MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/circulationaha.116.022802

Медицинская библиотека · Circulation · 2016

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.

Oldgren Jonas, Hijazi Ziad, Lindbäck Johan, Alexander John H, Connolly Stuart J, Eikelboom John W, Ezekowitz Michael D, Granger Christopher B, Hylek Elaine M, Lopes Renato D, Siegbahn Agneta, Yusuf Salim, Wallentin Lars, RE-LY and ARISTOTLE Investigators

СтатьяРандомизированное исследованиеВалидационное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Atrial fibrillation is associated with increased but variable risk of stroke. Our aim was to validate the recently developed biomarker-based ABC (age, biomarkers [high-sensitivity troponin and N-terminal fragment B-type natriuretic peptide], and clinical history of prior stroke/transient ischemic attack)-stroke risk score and compare its performance with the CHA2DS2VASc and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) risk scores.

METHODS

The ABC-stroke score includes age, biomarkers (N-terminal fragment B-type natriuretic peptide and high-sensitivity cardiac troponin), and clinical history (prior stroke). This validation was based on 8356 patients, 16 137 person-years of follow-up, and 219 adjudicated stroke or systemic embolic events in anticoagulated patients with atrial fibrillation in the RE-LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy). Levels of N-terminal fragment B-type natriuretic peptide, high-sensitivity cardiac troponin T (hs-cTnT), and high-sensitivity cardiac troponin I (hs-cTnI) were determined in plasma samples obtained at study entry.

RESULTS

The ABC-stroke score was well calibrated with 0.76 stroke/systemic embolic events per 100 person-years in the predefined low (<1%/y) risk group, 1.48 in the medium (1%-2%/y) risk group, and 2.60 in the high (>2%/y) risk group for the ABC-stroke score with hs-cTnT. Hazard ratios for stroke/systemic embolic events were 1.95 for medium- versus low-risk groups, and 3.44 for high- versus low-risk groups. ABC-stroke score achieved C indices of 0.65 with both hs-cTnT and hs-cTnI, in comparison with 0.60 for CHA2DS2VASc (P=0.004 for hs-cTnT and P=0.022 hs-cTnI) and 0.61 for ATRIA scores (P=0.005 hs-cTnT and P=0.034 for hs-cTnI).

CONCLUSIONS

The biomarker-based ABC-stroke score was well calibrated and consistently performed better than both the CHA2DS2VASc and ATRIA stroke scores. The ABC score should be considered an improved decision support tool in the care of patients with atrial fibrillation.

CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: ARISTOTLE, NCT00412984; RE-LY, NCT00262600.

Для цитирования: Oldgren Jonas, Hijazi Ziad, Lindbäck Johan, Alexander John H, Connolly Stuart J, Eikelboom John W, Ezekowitz Michael D, Granger Christopher B, Hylek Elaine M, Lopes Renato D, Siegbahn Agneta, Yusuf Salim, Wallentin Lars, RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.. Circulation. 2016. DOI: 10.1161/circulationaha.116.022802.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.